The European opposition against the BRCA gene patents

Familial Cancer

Volumn 5, Issue 1, 2006, Pages 95-102

  Matthijs, Gert ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

BRCA1; BRCA2; Familial breast cancer; Intellectual property; Licensing; Patenting

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CONFERENCE PAPER; COURT; DIAGNOSTIC TEST; EUROPE; FAMILIAL CANCER; GENE SEQUENCE; LICENSING; MOLECULAR CLONING; ONCOGENE; ORGANIZATION; PATENT; POLICY; PRIORITY JOURNAL; UNITED STATES;

BREAST NEOPLASMS; EUROPE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC RESEARCH; GENETICS; HUMANS; OVARIAN NEOPLASMS; PATENTS; POLICY MAKING;

EID: 33644892212     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-005-2580-6     Document Type: Conference Paper

References (15)

1. G Matthijs D Halley K Sperling S Kølvraa R Elles D Stoppa-Lyonnet 2002 Patents, monopolies on diagnostic tests: Europe's opposition against the BRCA1 patents Am J Hum Genet 71(suppl.) 182
2. European Patent Convention can be consulted at http://www3.european- patent-office.org/legal/epc/index.html.
3. JM Hall MK Lee B Newman JE Morrow LA Anderson B Huey MC. King 1990 Linkage of early-onset familial breast cancer to chromosome 17q21 Science 250 1684 9
4. R Wooster SL Neuhausen J Mangion Y Quirk D Ford N Collins K Nguyen S Seal T Tran D Averill 1994 Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13 Science 265 2088 90
5. Y Miki J Swensen D Shattuck-Eidens PA Futreal K Harshman S Tavtigian Q Liu C Cochran LM Bennett W Ding 1994 A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 66 71
6. PA Futreal Q Liu D Shattuck-Eidens C Cochran K Harshman S Tavtigian LM Bennett A Haugen-Strano J Swensen Y Miki 1994 BRCA1 mutations in primary breast and ovarian carcinomas Science 266 120 2
7. R Wooster G Bignell J Lancaster S Swift S Seal J Mangion N Collins S Gregory C Gumbs G Micklem 1995 Identification of the breast cancer susceptibility gene BRCA2 Nature 378 789 92
8. Directive 98/44/EC of the European Parliament and of the Council, 6 July 1998.
9. Minutes of the opposition proceedings available for consultation in the Online Public File Inspection at http://ofi.epoline.org/view/GetDossier.
10. Press release of February 1st 2005 available on www.myriad.com upon consultation on March 21st 2005.
11. Cancer Research UK. Charities to make breast cancer (BRCA2) gene freely available across Europe. Press release, 2004. (available at http://www. cancerresearchuk.org/news/pressreleases/breastcancergene_11feb04).
12. G Matthijs D Halley 2002 European-wide opposition against the breast cancer gene patents Eur J Hum Genet 10 783 5
13. Nuffield Council on Bioethics. The ethics of patenting DNA, a discussion paper. (Available via http://www.nuffieldbioethics.org/publications/ pp_0000000014.asp and launched on July 23, 2002).
14. Gene patenting: a BMA discussion paper. 2001 (available at http://www.bma.org.uk/ap.nsf/Content/Gene+patenting+paper).
15. European Patent Office. "Myriad/breast cancer" patent revoked after public hearing. Press release, 2004. (www.european-patent-office.org/news/ pressrel/2004_05_18_e.htm May 18, 2004).